Newport-based Xanodyne Pharmaceuticals Inc. has sold the global rights of women’s health product Lystedal to Ferring Pharmaceuticals, a privately owned specialty biopharmaceutical group headquartered in Switzerland. The sale is part of Xanodyne’s plan to tighten its focus on the pain management market, where it has a decade-long history with brands such as Darvocet and Roxicodone. The most recent addition to the company’s pain portfolio is Zipsor liquid-filled capsules, a non-steroidal anti-inflammatory drug that was approved by the FDA in June 2009. Financial details of the Xanodyne-Ferring transaction have not been disclosed.
-
Share This!
Newport
June 1, 2010
351 Views
You may also like
Popular Stories
Kentucky realtors reacting to NAR commission settlement
March 18, 2024
Construction projects to begin on UK’s south campus
March 18, 2024
Diageo NA expands Don’t Trash Glass recycling to Kentucky
March 18, 2024
Wild Eggs welcomes return of co-founder after 5 years
March 18, 2024
The Lane Report
- UofL Health opens $78M South Hospital in Bullitt County
- Wild Eggs welcomes return of co-founder after 5 years
- New Build-Ready location in Adair County is state’s 22nd
- New postage stamp dedicated at Bluegrass Hall of Fame
- Kentucky realtors reacting to NAR commission settlement
- Art Installation Unveiling: Hand-Painted Barrels at The Jockey’s Patio in the 5/3 Pavilion
- Pursuit Spirits Announces Release of Double Oaked Bourbon
- Store checkout fixture maker Pan-Oston investing $7M in expansion
- Construction projects to begin on UK’s south campus
- March mindfulness: Staying calm amidst the ‘Madness’
Add Comment